<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: The clinical relevance of the Revised European-American Classification of Lymphoid <z:hpo ids='HP_0002664'>Neoplasms</z:hpo> (REAL) is still debated </plain></SENT>
<SENT sid="1" pm="."><plain>To test the clinical validity of the REAL classification in Korea, where the incidence of T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is higher, we investigated the clinicopathological features of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) from Korea <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Center Hospital </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Five hundred and one patients with NHL were reclassified according to the REAL classification and clinicopathologically analysed </plain></SENT>
<SENT sid="3" pm="."><plain>Immunophenotypically, B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> accounted for 67.9% and T- and NK-cell type for 30.5% </plain></SENT>
<SENT sid="4" pm="."><plain>Approximately 48.5% of cases were forms of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), while only 5.4% were follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> unspecified (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e>-U; 10.8%) and angiocentric <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (11.8%) comprised the majority of T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Most of the angiocentric <z:hpo ids='HP_0002665'>lymphomas</z:hpo> presented with localized nasal/nasopharyngeal or tonsillar primaries </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e>) showed a significantly low overall survival compared to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (P = 0.02, log rank) </plain></SENT>
<SENT sid="8" pm="."><plain>Overall survival rates for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e>-U were also significantly different (P = 0.0043, log rank), though for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and angiocentric <z:hpo ids='HP_0002665'>lymphoma</z:hpo> there was no significant difference (P = 0.2142, log rank) </plain></SENT>
<SENT sid="9" pm="."><plain>Angiocentric <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, however, was characterized by a shorter median survival time than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (54 months vs. 96 months) </plain></SENT>
<SENT sid="10" pm="."><plain>Among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> patients according to the REAL classification, overall survival was significantly better in nonimmunoblastic type (intermediate-grade, WF-F,G) as compared to large cell <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> type (high-grade, WF-H) (log rank, P &lt; 0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>The morphological distinction of the <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> and nonimmunoblastic among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> of the REAL classification bears significant prognostic relevance worthy of further consideration </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: We conclude that lineage assignment (T vs. B) in the REAL classification is a clinically important distinction, but that it is necessary to subdivide the broad category of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
</text></document>